Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE: Durvalumab and Chemotherapy in Large Volume Stage III NSCLC
NCT04765709Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Mario Negri Institute for Pharmacological Research. Started Sep 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04765709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765709.